Clinical trial in Ireland challenges beliefs about Ozempic and similar new obesity treatments

A study carried out in St Vincent’s University Hospital (SVUH) Dublin challenges the belief that weight-loss medications such as Ozempic, Wegovy or Monjaro work just by promoting satiety and making you eat less. The randomized controlled trial with 30 patients was led by Professor Donal O’Shea, SVUH and UCD School of Medicine, and examined the family of medications based on the hormone Glucagon-like peptide-1 (GLP-1). The findings, published today in the Journal of the Obesity Society, show that there is a strong relationship between the increase in metabolic activity caused by once-daily treatment with GLP-1 and the amount of weight Read More